A Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Radiprodil in Patients With Tuberous Sclerosis Complex (TSC) or Focal Cortical Dysplasia (FCD) Type II
Latest Information Update: 11 Dec 2024
At a glance
- Drugs Radiprodil (Primary) ; Radiprodil (Primary)
- Indications Focal cortical dysplasia; Tuberous sclerosis
- Focus Adverse reactions; Pharmacokinetics
- Acronyms Astroscape
- Sponsors GRIN Therapeutics
Most Recent Events
- 08 Oct 2024 According to an GRIN Therapeutics Media Release, company announced that the initiation of treatment in the first patients enrolled in the study.
- 03 May 2024 New trial record